The Association for Molecular Pathology (AMP), a leading professional society in the field of molecular diagnostics, has announced its newly elected leadership for the 2027–2028 term. Known for its commitment to advancing molecular pathology, AMP continues to foster innovation through the engagement of expert volunteers across multiple specialized subdivisions.
Occupying the President-Elect position is Dr. Eric Q. Konnick of the University of Washington and Fred Hutch Cancer Center, underscoring AMP’s dedication to bridging academic research and clinical application. The Program Committee Chair-Elect, Dr. Matthew Lebo, hailing from Brigham and Women’s Hospital and Harvard Medical School, will steer AMP’s educational and scientific programming to new heights.
Each specialized subdivision within AMP now boasts renewed leadership to enhance progress in molecular diagnostics, addressing critical areas such as genetics, hematopathology, infectious diseases, informatics, and solid tumors. For example, in the Genetics Subdivision, Dr. Honey V. Reddi of Belay Diagnostics assumes the Chair role, leading efforts in hereditary condition diagnostics and translational research.
The Hematopathology Subdivision, focusing on malignancies and hematologic disorders, is represented by Dr. Wei Xie of Oregon Health and Science University, who will contribute to clinical practice advancements. Infectious Diseases Subdivision leadership under Dr. Esther Babady from bioMérieux highlights the ongoing importance of molecular diagnostics in detecting and managing infectious pathogens, a field revolutionized by rapid genomic technologies.
Informatics, an increasingly pivotal subset integrating data science with pathology, is chaired by Dr. Ryan Schmidt of Children’s Hospital Los Angeles and the University of Southern California. He will guide initiatives at the intersection of bioinformatics and clinical diagnostics, crucial for interpreting complex molecular datasets.
The Solid Tumors Subdivision, critical for oncology diagnostics, features Dr. Sinchita Roy–Chowdhuri of MD Anderson Cancer Center as Clinical Practice Committee Representative, emphasizing precision medicine approaches in cancer detection and treatment planning.
AMP’s leadership reflects a multi-disciplinary approach including pathologists, bioinformaticians, and translational scientists. Their collective expertise drives innovation in molecular diagnostics, ensuring the development and implementation of high-quality, clinically relevant testing. This leadership will play an instrumental role in shaping policies, education, and collaborative efforts globally.
Founded in 1995, AMP supports over 3,100 professionals dedicated to molecular diagnostics spanning bioinformatics, oncology, infectious diseases, and genetic disorders. The society remains at the forefront of evolving diagnostic methodologies, advocating for policies that promote patient access to state-of-the-art molecular testing technologies.
As molecular diagnostics burgeons in healthcare, the new AMP leaders’ vision will be pivotal in advancing research, refining clinical practices, and integrating cutting-edge computational tools. Their stewardship is expected to catalyze significant progress in personalized medicine and diagnostic precision.
Subject of Research: Molecular Diagnostics and Molecular Pathology Leadership
Article Title: AMP Announces 2027–2028 Leadership to Drive Molecular Diagnostics Innovation
News Publication Date: Not specified
Web References: www.amp.org
Keywords: Molecular Diagnostics, Molecular Pathology, Genetics, Hematopathology, Infectious Diseases, Bioinformatics, Solid Tumors, Personalized Medicine, Clinical Practice
